New genetic marker for piperaquine resistance in Plasmodium falciparum

February 1, 2017 at 2:03 pm

Lancet Infectious Diseases February 2017 V.17 N.2 P.119–121

COMMENT

Arjen M Dondorp

In the Greater Mekong subregion, Plasmodium falciparum resistance to artemisinins is increasingly compounded by concurrent resistance to partner drugs in combination therapies, which results in high treatment failure rates. Artemisinin combination therapies are first-line drugs for the treatment of falciparum malaria in all endemic countries; new antimalarials will probably not be marketed within this decade. Clinical drug efficacy studies are time and resource consuming and availability of molecular markers for drug resistance can facilitate near real-time monitoring, which is needed for guiding policy changes towards locally effective combination therapies in the Greater Mekong subregion. Markers are available for artemisinin resistance (Kelch13 mutations8) and mefloquine resistance (mdr1 amplification9). Markers for other artemisinin partner drugs used in the region, including lumefantrine, amodiaquine, and piperaquine, are less well defined….

FULL TEXT

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30414-5/fulltext?elsca1=etoc

PDF

http://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(16)30414-5.pdf

Advertisements

Entry filed under: Antiparasitarios, Biología Molecular, Epidemiología, FIEBRE en el POST-VIAJE, Infecciones parasitarias, Metodos diagnosticos, Sepsis, Update, Zoonosis.

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Dihydroartemisinin-piperaquine: if it works for control, can we use it for elimination?


Calendar

February 2017
M T W T F S S
« Jan   Mar »
 12345
6789101112
13141516171819
20212223242526
2728  

Most Recent Posts


%d bloggers like this: